UNITED STATES OF AMERICA —Pathos AI has closed a USD 237 million Series E financing round, led by pharmaceutical company Bristol Myers Squibb, alongside existing backers. The transaction establishes a post-money valuation of approximately USD 3 billion for the New York-based clinical-stage biotechnology firm. Concurrently, the organization announced a five-year, USD 55 million data licensing agreement with Tempus AI to construct a specialized longitudinal dataset focused on Alzheimer disease and other neurological conditions.
Pathos AI is a technology-driven drug development organization that integrates advanced machine learning into therapeutic discovery. The company utilizes its proprietary Foundry platform, which deploys thousands of specialized artificial intelligence agents to synthesize clinical, genomic, and competitive data in real time. This infrastructure enables continuous probability-of-success calculations, allowing for dynamic clinical trial adjustments and early elimination of high-risk development pathways.
This capital injection highlights institutional confidence in agentic artificial intelligence to address inefficiencies in pharmaceutical research and development. By shifting from static data analysis to continuous, autonomous decision-making, biotechnology firms can optimize patient stratification and accelerate the identification of viable therapeutic candidates. The development impacts the biotechnology, pharmaceutical, and health technology sectors, providing a framework for reducing clinical trial failure rates and associated capital expenditures.
For Bristol Myers Squibb, the investment secures non-exclusive strategic access to the Foundry platform across its broader research and development portfolio, coupled with three-year exclusive rights to apply these capabilities within its neuroscience division. The funding will primarily accelerate the internal oncology pipeline of Pathos AI, advancing assets such as a novel TROP2 and HER3 bispecific antibody-drug conjugate toward registrational studies. Additional capital will support the clinical progression of programs targeting metastatic castration-resistant prostate cancer, multiple myeloma, and specific kinase inhibitors, reinforcing a multi-asset approach to precision medicine.
